Scarica l'app Stockscreener
26.22
2.55%
0.6816
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
Quest Partners LLC Purchases 32,884 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Finansavisen - Finansavisen
IDEAYA Biosciences (NASDAQ:IDYA) Earns Overweight Rating from Analysts at Stephens - MarketBeat
Ideaya Biosciences Names Chief Commercial Officer - Contract Pharma
IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer - Marketscreener.com
Stephens & Co. Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight Recommendation - MSN
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year LowTime to Sell? - MarketBeat
Ideaya Biosciences stock hits 52-week low at $27.51 - Investing.com India
500: Something went wrong - Investing.com Canada
Ideaya Biosciences stock hits 52-week low at $27.51 By Investing.com - Investing.com UK
Janus Henderson Group PLC's Strategic Acquisition in IDEAYA Bios - GuruFocus.com
IDEAYA Biosciences' SWOT analysis: biotech stock's potential in uveal melanoma treatment - Investing.com Australia
(IDYA) Investment Analysis - Stock Traders Daily
FMR LLC's Strategic Acquisition of IDEAYA Biosciences Inc Shares - GuruFocus.com
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise - 뉴스와이어
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day - BioSpace
IDEAYA Biosciences Announces Participation Jefferies London | Trending From Our Network - Chicago Star Media
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen - The Malaysian Reserve
Ideaya nominates B7H3/PTK7 bispecific ADC as development candidate - BioWorld Online
IDEAYA Announces Development Candidate Nomination of IDE034 | Trending From Our Network - Chicago Star Media
Fiera Capital Corp Sells 45,590 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Research Analysts Set Expectations for IDYA FY2024 Earnings - MarketBeat
90,000 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Purchased by General American Investors Co. Inc. - MarketBeat
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know - Yahoo Finance
The 3.2% return this week takes IDEAYA Biosciences' (NASDAQ:IDYA) shareholders five-year gains to 258% - Simply Wall St
Leerink Partnrs Issues Optimistic Estimate for IDYA Earnings - MarketBeat
FY2024 EPS Forecast for IDEAYA Biosciences Raised by Analyst - MarketBeat
Leerink Partnrs Downgrades IDEAYA Biosciences (NASDAQ:IDYA) to Hold - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Trading Down 4.5%Here's Why - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Issues Quarterly Earnings Results - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to Market Perform at Leerink Partners - MarketBeat
IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023) - Yahoo Finance
Wedbush Reiterates "Outperform" Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences: Q3 2024 Financial and Clinical Progress - TipRanks
IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire
abrdn plc Buys Shares of 232,830 IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Ideaya Biosciences stock hits 52-week low at $28.04 By Investing.com - Investing.com South Africa
IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 1-Year LowHere's What Happened - MarketBeat
Ideaya Biosciences stock hits 52-week low at $28.04 - Investing.com
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Financial Times
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinic - GuruFocus.com
Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline - MSN
IDEAYA Biosciences' (IDYA) "Outperform" Rating Reaffirmed at Oppenheimer - MarketBeat
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - The Malaysian Reserve
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors – Company AnnouncementFT.com - Financial Times
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase D - GuruFocus.com
WRN inhibitor IDE-275 gains IND clearance for phase I study in MSI-high tumors - BioWorld Online
IDEAYA Biosciences Reports Encouraging Clinical Data for IDE397 in MTAP-Deletion Urothelial Cancer and NSCLC - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $55.45 Average Price Target from Brokerages - MarketBeat
IDYAIDEAYA Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 - Quantisnow
Leerink Partnrs Has Pessimistic View of IDYA Q3 Earnings - MarketBeat
UBS Group Initiates Coverage on IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
Where are the Opportunities in (IDYA) - Stock Traders Daily
Analysts Offer Predictions for IDYA FY2024 Earnings - MarketBeat
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):